Die Zinsentscheidungen der Schweizer und der US-Notenbank sowie die Abstimmung in Deutschland über das geplante Finanzpaket ...
Zacks Investment Research on MSN2d
Merck (MRK) Advances While Market Declines: Some Information for InvestorsIn the latest market close, Merck (MRK) reached $94.71, with a +1.46% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and the ...
Von Donald Trump bis Friedrich Merz: Die Politik bestimmt zunehmend die Richtung an den Finanzmärkten, ist Robert Greil ...
Positive Äußerungen von Notenbankchef Powell zur Konjunktur sind bei den Anlegern gut angekommen. Die Wall-Street-Indizes ...
Robert Greil rechnet mit einer weiteren Leitzinssenkung der EZB. Zudem blickt er besonders auf die Auftragseingänge der ...
Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...
Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...
Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback